BVF Partners OS Ltd.
CIK 1660684 · last filed 2025-08-07
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
CTIC price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
GRAND CAYMAN, E9 KY1-1104
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ESSA Pharma Inc. (EPIX) Delisted | 4,726,809 | $0.20 | $951.0K | -$2.9K | 1 | 2025-08-07 | |
| ELDN | 145,029 | $2.21 | $320.5K | $0 | 1 | 2023-05-09 | |
| CTI BIOPHARMA CORP (CTIC) Delisted | Director | 62,978 | $9.09 | $572.5K | -$520.20M | 1 | 2022-08-11 |
| Merus N.V. (MRUS) Delisted | 311,210 | $90.00 | $28.01M | -$432.55M | 2 | 2021-07-07 | |
| Eledon Pharmaceuticals, Inc. (NVUS) Delisted | 771,780 | — | — | $0 | 1 | 2020-12-28 | |
| OLMA | 3,392,663 | $6.62 | $22.46M | $215.71M | 1 | 2020-11-20 | |
| XOMA Royalty Corp (XOMA) Delisted | 1,941,035 | $40.17 | $77.97M | $5.47M | 1 | 2020-08-25 | |
| KYMR | 1,359,109 | $114.84 | $156.08M | $0 | 1 | 2020-08-25 | |
| CYTK | 2,350,829 | $60.73 | $142.77M | -$118.47M | 1 | 2020-02-18 | |
| FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | 3,648,474 | $38.00 | $138.64M | $30.45M | 2 | 2019-12-11 | |
| INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | 5,815,887 | $0.04 | $260.0K | $8.55M | 1 | 2018-11-15 | |
| CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted | 291,788 | $8.37 | $2.44M | $36.80M | 1 | 2017-10-23 | |
| ALPINE IMMUNE SCIENCES, INC. (NVLS) Delisted | 163,342 | — | — | $3.04M | 2 | 2017-05-19 |
Recent Filings · Page 2 of 2
17 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-12-11 | FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Buy (P) | +945,000 | $3.80M | EDGAR |
| 2019-11-26 | FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Buy (P) | +7,840,070 | $26.66M | EDGAR |
| 2018-11-15 | INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | Buy (P) | +6,341,524 | $8.55M | EDGAR |
| 2018-04-06 | — | Sell (S) | −16,111,067 | -$46.72M | |
| 2017-10-23 | CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted | Buy (P) | +2,323,412 | $36.80M | EDGAR |
| 2017-05-19 | ALPINE IMMUNE SCIENCES, INC. (NVLS) Delisted | Buy (P) | +552,006 | $1.27M | EDGAR |
| 2017-05-11 | ALPINE IMMUNE SCIENCES, INC. (NVLS) Delisted | Buy (P) | +763,238 | $1.77M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.